WO2016141548A1 - 一种制备高纯度磺胺化合物的方法及其中间体 - Google Patents

一种制备高纯度磺胺化合物的方法及其中间体 Download PDF

Info

Publication number
WO2016141548A1
WO2016141548A1 PCT/CN2015/073945 CN2015073945W WO2016141548A1 WO 2016141548 A1 WO2016141548 A1 WO 2016141548A1 CN 2015073945 W CN2015073945 W CN 2015073945W WO 2016141548 A1 WO2016141548 A1 WO 2016141548A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
sulfonamide
group
sulfonamide compound
solvent
Prior art date
Application number
PCT/CN2015/073945
Other languages
English (en)
French (fr)
Inventor
梁小敏
姜浩
滕海鸽
杨金志
周君津
章金龙
陈邦池
Original Assignee
泸州东方农化有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 泸州东方农化有限公司 filed Critical 泸州东方农化有限公司
Priority to CN201580075876.5A priority Critical patent/CN107406450B/zh
Priority to PCT/CN2015/073945 priority patent/WO2016141548A1/zh
Priority to BR112017019116-4A priority patent/BR112017019116B1/pt
Publication of WO2016141548A1 publication Critical patent/WO2016141548A1/zh
Priority to US15/700,136 priority patent/US9950997B2/en
Priority to US15/924,225 priority patent/US10221128B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0215—Sulfur-containing compounds
    • B01J31/0222—Sulfur-containing compounds comprising sulfonyl groups
    • B01J31/0224—Sulfur-containing compounds comprising sulfonyl groups being perfluorinated, i.e. comprising at least one perfluorinated moiety as substructure in case of polyfunctional compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/53—X and Y not being nitrogen atoms, e.g. N-sulfonylcarbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2527/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • C07C2527/24—Nitrogen compounds

Definitions

  • the invention relates to the synthesis of organic sulfur compounds, in particular to a method for synthesizing high-purity sulfonamide compounds and intermediates thereof.
  • Sulfonamides (I) are a class of very important organic sulfur compounds with a wide range of pesticide uses.
  • Diclosulam, N-(2,6-dichlorophenyl)-5-ethoxy-7-fluoro-1,2,4-triazole developed by Dow Agricultural Sciences, USA And [1,5-c]pyrimidine-2-sulfonamide
  • Diclostrimine is an acetolactate synthase (ALS) inhibitor that acts by the rapid absorption of weeds through the roots and stems and leaves. Suitable for crop soybeans, peanut fields, pre-planting soil treatment to control broad-leaved weeds, and for controlling post-emergence winter wheat field broad-leaved weeds.
  • Diclostrim can be prepared by the condensation of 2,6-dichloroaniline and triazolopyrimidinesulfonyl chloride. Due to the steric hindrance of 2,6-dichloroaniline, it is compatible with triazolopyrimidinesulfonyl chloride. The condensation reaction is slow and the yield is low, which in turn leads to low purity of the product. Although US5973148 has been modified for this reaction to increase the reaction yield, it still contains 3% triazolopyrimidine sulfonic acid in the product. Due to its chemical and physical properties, chlorfenapyr cannot be effectively purified by alkali-soluble acid precipitation. Further, since the solubility of diclosilamide in a conventional solvent is small, it is difficult to obtain high-purity diclostrim by recrystallization while taking into consideration the yield.
  • herbicides such as mefenacetamide (Sulfentrazone, N-(2,4-dichloro-5-[4-difluoromethyl-4,5-dihydro-3-methyl-5-oxo- 1H-1,2,4-triazol-1-yl)phenyl]methanesulfonamide, WO 8703782), chlorosulphonamide (Cloransulam methyl, 3-chloro-2-[(5-ethoxy-7) -Fluoro-1,2,4-triazolo[1,5-c]pyrimidin-2-yl)sulfonylamino]benzoic acid methyl ester, US 5,163,995), diflufenacil (Florasulam, N-(2, 6-Difluorophenyl)-5-ethoxy-8-fluoro-1,2,4-triazolo[1,5-c]pyrimidine-2-sulfonamide, US 5163995), penoxsul
  • the object of the present invention is to overcome the above-mentioned shortcomings of the prior art and to provide a method for preparing a high-purity sulfonamide compound and an intermediate thereof to meet the needs of scientific research and industrial production.
  • a method of preparing a high purity sulfonamide compound comprises the steps of:
  • the crude compound of the sulfonamide compound (I) is used as a starting material, and the compound of the formula (III) is synthesized by reacting a compound of the formula (II) with a solvent, a base and a catalyst;
  • R is a methyl group or an aryl or heteroaryl group as shown below:
  • Ar is an aryl or heteroaryl group as shown below:
  • X is a halogen or a tert-butoxycarbonyloxy group
  • Y is a C1-C6 alkyl group, a C6-C12 aryl group or a tert-butoxy group.
  • the X is preferably Cl or a tert-butoxycarbonyloxy group
  • Y is preferably a C1-C6 alkyl group or a tert-butoxy group.
  • the molar ratio of the compound (II) to the crude sulfonamide compound (I) is from 0.8 to 2:1.
  • the base described in the first step is an organic base; the molar ratio of the organic base to the crude sulfonamide compound (I) is from 1 to 2:1, the catalyst is 4-dimethylaminopyridine, and the catalyst and the sulfonamide compound (I) are crude.
  • the weight percentage is 0.05-10%, and the solvent is a halogenated hydrocarbon, an ether or a nitrile, and the reaction temperature is -10 ° C to 80 ° C.
  • the organic base described in the first step is preferably triethylamine, DBU or pyridine, and the molar ratio of the organic base to the crude sulfonamide compound (I) is preferably from 1 to 1.3:1, and the catalyst and the sulfonamide compound (I) are crude.
  • the weight percentage is preferably from 0.1 to 5%, and the solvent is preferably dichloromethane, tetrahydrofuran or acetonitrile, and the reaction temperature is preferably from 0 °C to 40 °C.
  • the base in the second step is a hydroxide, a carbonate or a hydrogencarbonate of an alkali metal and an alkaline earth metal, and the molar ratio of the base to the compound (III) is 0.5 to 1.5:1, and the solvent is methanol or ethanol.
  • the reaction temperature is 0 ° C ⁇ 80 ° C; or the acid described in the second step is an inorganic or organic acid, the molar ratio of acid to compound (III) is 0.5 ⁇ 1.5 :1, the solvent is methanol, ethanol, isopropanol, acetonitrile, acetone, DMF or DMSO, and the reaction temperature is 0 ° C to 80 ° C.
  • the base described in the second step is preferably sodium carbonate, potassium carbonate, sodium hydrogencarbonate or potassium hydrogencarbonate, the molar ratio of the base to the compound (III) is preferably from 0.75 to 1.25:1, the solvent is preferably ethanol, and the reaction temperature is preferably 10 °C ⁇ 60°C; or the acid described in the second step is preferably hydrochloric acid, sulfuric acid or trifluoroacetic acid, the molar ratio of the acid to the compound (III) is preferably 0.75 to 1.25:1, the solvent is preferably ethanol, and the reaction temperature is preferably 10 °C ⁇ 60 °C.
  • the present invention provides a class of sulfonamide compounds having a compound structure as shown in formula (III):
  • R is a methyl group or an aryl or heteroaryl group as shown below:
  • Ar is an aryl or heteroaryl group as shown below:
  • Y is a C1-C6 alkyl group, a C6-C12 aryl group or a tert-butoxy group.
  • the Y is preferably a C1-C6 alkyl group or a tert-butoxy group.
  • the invention is characterized in that the crude sulfonamide compound (I) which has low solubility in a conventional solvent and is difficult to be purified is firstly converted. Purification of the intermediate (II) which is easily soluble in a conventional solvent, followed by simple hydrolysis to obtain a highly pure sulfonamide compound (I).
  • the sulfonamide compound obtained by the invention has an HPLC purity of 99.9% or more.
  • the reagent used in the invention is cheap, simple in operation, high in yield, high in purity of the obtained product, and has great application value for research and production of sulfonamides.

Abstract

一种制备高纯度磺胺化合物的方法及其中间体。所述方法包括如下步骤：第一步，以磺胺化合物(I)粗品为起始原料，在碱和催化剂作用下与式(II)化合物反应合成式(III)中间体，第二步，将式(III)所示化合物和碱或酸反应，制得高纯度的磺胺化合物(I)。

Description

一种制备高纯度磺胺化合物的方法及其中间体 技术领域
本发明涉及有机硫化合物的合成，尤其涉及一种高纯度磺胺化合物合成方法及其中间体。
背景技术
磺胺化合物(I)是一类非常重要的有机硫化合物，具有广泛的农药用途。例如，由美国陶氏农业科学公司开发的双氯磺草胺(Diclosulam，N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺)是一种三唑并嘧啶类磺酰胺高效除草剂(US5163995)。双氯磺草胺是乙酰乳酸合成酶(ALS)抑制剂，其可被杂草通过根部和茎叶快速吸收而发挥作用。适宜作物大豆、花生田苗前种植土壤处理防除阔叶杂草，以及用于苗后防除冬小麦田阔叶杂草。
双氯磺草胺可通过2,6-二氯苯胺和三氮唑并嘧啶磺酰氯缩合制备，由于2,6-二氯苯胺的空间位阻极大，其与三氮唑并嘧啶磺酰氯的缩合反应速度慢，收率低，进而导致产物的纯度不高。尽管US5973148对该反应进行了改进，提高了反应收率，但是在产物中仍然含有3％的三氮唑并嘧啶磺酸。双氯磺草胺由于其化学物理性质，不能通过碱溶酸析进行有效精制。此外，由于双氯磺草胺在常规溶剂中的溶解度都很小，很难在兼顾收率的同时通过重结晶的方法获得高纯度的双氯磺草胺。
其它新型高效除草剂如甲磺草胺(Sulfentrazone，N-(2,4-二氯-5-[4-二氟甲基-4,5-二氢-3-甲基-5-氧代-1H-1,2,4-三唑-1-基)苯基]甲磺酰胺，WO 8703782)，氯酯磺草胺(Cloransulam methyl，3-氯-2-[(5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-基)磺酰氨基]苯甲酸甲酯，US5163995)，双氟磺草胺(Florasulam，N-(2,6-二氟苯基)-5-乙氧基-8-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺，US 5163995)，五氟磺草胺(Penoxsulam，2-(2,2-二氟乙氧基)-N-(5,8-二甲氧基-1,2,4-三唑并[1,5-c]嘧啶-2-基)-6-三氟甲基苯磺酰胺，US 5858924)，唑嘧磺草胺(Flumetsulam,N-(2,6-二氟苯基)-5-甲基-1,2,4-三唑并[1,5-a]嘧啶-2-磺酰胺，US 4910306)，啶磺草胺(Pyroxsulam，N-(5,7-二甲氧基-1,2,4-三唑并[1,5-a]嘧啶-2-基)-2-甲氧基-4-三氟甲基-3-吡啶磺酰胺，WO 2002036595)，磺草唑胺(Metosulam，N-(2,6-二氯-3-甲基苯基)-5,7-二甲氧基-1,2,4-三唑[1,5-a]嘧啶-2-磺酰胺，EP 0142152)等，因其类似的化学和物理性质，存在类似的技术难处。
发明内容
本发明的目的是为了克服上述现有技术的缺点，提供一种制备高纯度磺胺化合物的方法及其中间体，以满足科研及工业化生产的需要。
一种制备高纯度磺胺化合物的方法包括如下步骤：
第一步，以磺胺化合物(Ⅰ)粗品为起始原料，在溶剂、碱和催化剂作用下与式(II)化合物反应合成式(III)化合物；
第二步，将式(III)所示化合物在溶剂中与碱或酸反应，制得高纯度的磺胺化合物(I)；反应通式如下：
Figure PCTCN2015073945-appb-000001
其中，R为甲基或如下所示的芳基或杂芳基：
Figure PCTCN2015073945-appb-000002
Ar为如下所示的芳基或杂芳基：
Figure PCTCN2015073945-appb-000003
X为卤素或叔丁氧基羰氧基，
Y为C1-C6烷基，C6-C12芳基或叔丁氧基。
所述的X优选为Cl或叔丁氧基羰氧基，Y优选为C1-C6烷基或叔丁氧基。
化合物(II)与磺胺化合物(Ⅰ)粗品的摩尔比为0.8～2:1。
第一步所述的碱为有机碱；有机碱与磺胺化合物(Ⅰ)粗品的摩尔比为1～2:1，所述的催化剂为4-二甲氨基吡啶，催化剂与磺胺化合物(Ⅰ)粗品的重量百分比为0.05～10％，所述的溶剂为卤代烃、醚类或腈类，所述的反应温度为-10℃～80℃。
第一步所述的有机碱优选为三乙胺、DBU或吡啶，所述的有机碱与磺胺化合物(Ⅰ)粗品的摩尔比优选为1～1.3:1，催化剂与磺胺化合物(Ⅰ)粗品的重量百分比优选为0.1～5％，所述的溶剂优选为二氯甲烷、四氢呋喃或乙腈，所述的反应温度优选为0℃～40℃。
第二步所述的碱为碱金属和碱土金属的氢氧化物、碳酸盐、碳酸氢盐，碱与化合物(III)的摩尔比为0.5～1.5:1，所述的溶剂为甲醇、乙醇、异丙醇、乙腈、丙酮、DMF或DMSO，反应温度为0℃～80℃；或第二步所述的酸为无机酸或有机酸，酸与化合物(III)的摩尔比为0.5～1.5:1，溶剂为甲醇、乙醇、异丙醇、乙腈、丙酮、DMF或DMSO，反应温度为0℃～80℃。
第二步所述的碱优选为碳酸钠、碳酸钾、碳酸氢钠或碳酸氢钾，碱与化合物(III)的摩尔比优选为0.75～1.25:1，溶剂优选为乙醇，反应温度优选为10℃～60℃；或第二步所述的酸优选为盐酸、硫酸或三氟醋酸，酸与化合物(III)的摩尔比优选为0.75～1.25:1，溶剂优选为乙醇，反应温度优选为10℃～60℃。
本发明提供了一类磺胺化合物，其化合物结构如式(III)所示：
Figure PCTCN2015073945-appb-000004
其中，R为甲基或如下所示的芳基或杂芳基：
Figure PCTCN2015073945-appb-000005
Ar为如下所示的芳基或杂芳基：
Figure PCTCN2015073945-appb-000006
Y为C1-C6烷基，C6-C12芳基或叔丁氧基。
所述的Y优选为C1-C6烷基或叔丁氧基。
本发明与现有技术相比具有的有益效果：
本发明的特点在于将在常规溶剂中溶解度小、纯化困难的磺胺化合物(Ⅰ)粗品先转化 为易溶于常规溶剂的中间体(II)进行纯化，然后经过简单的水解制得高纯度的磺胺化合物(Ⅰ)。采用该发明所制得的磺胺化合物HPLC纯度能达到99.9％以上。
该发明所采用的试剂便宜，操作简单，收率高，所制得的产品纯度高，对于磺胺类药物的科研及生产具有很大的应用价值。
具体实施方式
为了能够更清楚地理解本发明的技术内容，下面结合实施例对本发明做进一步的阐述，但这些实施例不对本发明构成任何限制。
实施例1 N-乙酰基-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺的制备
室温下，将N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺粗品(HPLC纯度95.8％)(10.0g，1.0eq)，DMAP(0.01g)，乙腈(100mL)，三乙胺(3.0g，1.2eq)依次投入250mL反应瓶中，滴加乙酰氯(2.1g，1.1eq)。滴加完毕继续反应3h，HPLC监测原料反应完全，停止反应，蒸除乙腈后加入水，用二氯甲烷提取三次，合并有机相，盐水洗涤后无水硫酸镁干燥，过滤浓缩得到的白色固体用乙醇浆洗，干燥后得到10.3g白色固体，HPLC纯度99.1％。1H NMR(400MHz,D6-DMSO)δ:7.72(m,2H)，7.62(m,1H),7.50(s,1H),4.73(m,2H),2.12(s,3H),1.48(m,3H)。
实施例2 N-(2-溴乙酰基)-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺的制备
室温下，将N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺粗品(HPLC纯度95.8％)(10.0g，1.0eq)，DMAP(0.01g)，THF(100mL)，三乙胺(3.0g，1.2eq)依次投入250mL反应瓶中，滴加溴乙酰溴(5.5g，1.1eq)。滴加完毕继续反应2h，HPLC监测原料反应完全，停止反应，蒸除THF后加入水，用二氯甲烷提取三次，合并有机相，盐水洗涤后无水硫酸镁干燥，过滤浓缩得到的白色固体用乙醇浆洗，干燥后得到12.3g白色固体，HPLC纯度99.5％。1H NMR(400MHz,D6-DMSO)δ:7.76(m,2H),7.68(m,1H),7.57(s,1H),4.87(s,2H),4.76(m,2H),1.50(m,3H)。
实施例3 N-(2-氯乙酰基)-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺的制备
室温下，将N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺粗品(HPLC纯度95.8％)(10.0g，1.0eq)，DMAP(0.01g)，THF(100mL)，三乙胺(3.0g，1.2eq)依次 投入250mL反应瓶中，滴加氯乙酰氯(3.1g，1.1eq)。滴加完毕继续反应2h，HPLC监测原料反应完全，停止反应，蒸除THF后加入水，用二氯甲烷提取三次，合并有机相，盐水洗涤后无水硫酸镁干燥，过滤浓缩得到的白色固体用乙醇浆洗，干燥后得到11.4g白色固体，HPLC纯度99.3％。1H NMR(400MHz,D6-DMSO)δ:7.72(m,2H),7.62(m,1H),7.50(s,1H),4.97(s,2H),4.73(m,2H),1.48(m,3H)。
实施例4 N-(2,2-二氯乙酰基)-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺的制备
室温下，将N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺粗品(HPLC纯度95.8％)(10.0g，1.0eq)，DMAP(0.01g)，THF(100mL)，三乙胺(3.0g，1.2eq)依次投入250mL反应瓶中，滴加二氯乙酰氯(4.0g，1.1eq)。滴加完毕继续反应1h，HPLC监测原料反应完全，停止反应，蒸除THF后加入水，用二氯甲烷提取三次，合并有机相，盐水洗涤后无水硫酸镁干燥，过滤浓缩得到的白色固体用乙醇浆洗，干燥后得到11.6g白色固体，HPLC纯度99.0％。1H NMR(400MHz,D6-DMSO)δ:7.75(m,2H),7.63(m,1H),7.54(s,1H),6.80(s,1H),4.78(m,2H),1.46(m,3H)。
实施例5 N-苯甲酰基-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺的制备
采用类似实施例1的方法，制得N-苯甲酰基-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺，白色固体，HPLC纯度98.7％。1H NMR(400MHz,D6-DMSO)δ:7.95～6.86(m,9H),3.98(m,2H),1.33(m,3H)。
实施例6 N-(2-甲氧基乙酰基)-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺的制备
采用类似实施例1的方法，制得N-(2-甲氧基乙酰基)-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺，白色固体，HPLC纯度98.8％。1H NMR(400MHz,D6-DMSO)δ:7.70～7.71(m,2H),7.60～7.61(m,H),7.49(s,H),4.74(q,2H),4.57(s,3H),1.47(t,3H)。
实施例72-(2,2-二氟乙氧基)-N-(2-氯乙酰基)-N-(5,8-二甲氧基-1,2,4-三唑并[1,5-c]嘧啶-2-基)-6-三氟甲基苯磺酰胺的制备
采用类似实施例1的方法，制得2-(2,2-二氟乙氧基)-N-(2-氯乙酰基)-N-(5,8-二甲氧基-1,2,4-三唑并[1,5-c]嘧啶-2-基)-6-三氟甲基苯磺酰胺，白色固体，HPLC纯度98.9％。1H NMR(400MHz,D6-DMSO)δ:7.72～7.96(m,4H)，6.75(t,1H)，4.77(m,2H)，4.35(s,2H)，4.20(s, 3H)，4.04(s,3H)。
实施例82-(2,2-二氟乙氧基)-N-乙酰基-N-(5,8-二甲氧基-1,2,4-三唑并[1,5-c]嘧啶-2-基)-6-三氟甲基苯磺酰胺的制备
采用类似实施例1的方法，制得2-(2,2-二氟乙氧基)-N-乙酰基-N-(5,8-二甲氧基-1,2,4-三唑并[1,5-c]嘧啶-2-基)-6-三氟甲基苯磺酰胺，白色固体，HPLC纯度98.7％。1H NMR(400MHz,D6-DMSO)δ:7.70～7.92(m,4H)，6.76(t,1H)，4.78(m,2H)，4.20(s,3H)，4.02(s,3H)，1.95(s,3H)。
实施例92-(2,2-二氟乙氧基)-N-苯甲酰基-N-(5,8-二甲氧基-1,2,4-三唑并[1,5-c]嘧啶-2-基)-6-三氟甲基苯磺酰胺的制备
采用类似实施例1的方法，制得2-(2,2-二氟乙氧基)-N-苯甲酰基-N-(5,8-二甲氧基-1,2,4-三唑并[1,5-c]嘧啶-2-基)-6-三氟甲基苯磺酰胺，白色固体，HPLC纯度99.0％。1H NMR(400MHz,D6-DMSO)δ:7.31～7.96(m,9H)，6.35(t,1H)，4.64(m,2H)，4.13(s,3H)，3.94(s,3H)。
实施例102-(2,2-二氟乙氧基)-N-(2-甲氧基乙酰基)-N-(5,8-二甲氧基-1,2,4-三唑并[1,5-c]嘧啶-2-基)-6-三氟甲基苯磺酰胺的制备
采用类似实施例1的方法，制得2-(2,2-二氟乙氧基)-N-(2-甲氧基乙酰基)-N-(5,8-二甲氧基-1,2,4-三唑并[1,5-c]嘧啶-2-基)-6-三氟甲基苯磺酰胺，白色固体，HPLC纯度98.8％。1H NMR(400MHz,D6-DMSO)δ:7.70～7.92(m,4H)，6.70(t,1H)，4.74(m,2H)，4.17(s,3H)，3.99(s,3H)，3.82(s,2H)，3.13(s,3H)。
实施例11 N-(2-甲氧基乙酰基)-3-氯-2-[(5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-基)磺酰氨基]苯甲酸甲酯的制备
采用类似实施例1的方法，制得N-(2-甲氧基乙酰基)-3-氯-2-[(5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-基)磺酰氨基]苯甲酸甲酯，HPLC纯度95.9％。1H NMR(400MHz,D6-DMSO)δ:7.99(t,2H)，7.73(t,1H)，7.46(s,1H)，4.74(q,2H)，3.69(s,1H)，3.67(s,3H)，3.28(s,3H)，1.98(s,1H)，1.50(t,3H)。
实施例12 N-苯甲酰基-3-氯-2-[(5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-基)磺酰氨基]苯甲酸甲酯的制备
采用类似实施例1的方法，制得N-苯甲酰基-3-氯-2-[(5-乙氧基-7-氟-1,2,4三唑并[1,5-c]嘧啶-2-基)磺酰氨基]苯甲酸甲酯，HPLC纯度99.1％。1H NMR(400MHz,D6-DMSO)δ:7.87～7.89(m,2H)，7.60～7.62(m,1H)，7.52～7.53(m,2H)，7.40～7.43(m,2H)，7.28～7.31(m,2H)，4.74(q,2H)，3.78(s,3H)，1.51(t,3H)。
实施例13 N-乙酰基-3-氯-2-[(5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-基)磺酰氨基]苯甲酸甲酯的制备
采用类似实施例1的方法，制得N-乙酰基-3-氯-2-[(5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-基)磺酰氨基]苯甲酸甲酯，HPLC纯度99.2％。1H NMR(400MHz,D6-DMSO)δ:7.94～7.98(m,2H)，7.71(t,1H)，7.45(s,1H)，4.73(t,2H)，3.66(s,3H)，1.49(t,3H)。
实施例14 N-(2-氯乙酰基)-3-氯-2-[(5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-基)磺酰氨基]苯甲酸甲酯的制备
采用类似实施例1的方法，制得N-(2-氯乙酰基)-3-氯-2-[(5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-基)磺酰氨基]苯甲酸甲酯，HPLC纯度98.2％。1H NMR(400MHz,D6-DMSO)δ:7.97～8.02(m,2H)，7.76(t,1H)，7.46(s,1H)，4.73(q,2H)，3.66(s,3H)，1.50(t,3H)。
实施例15 N-(2,2-二氯乙酰基)-3-氯-2-[(5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-基)磺酰氨基]苯甲酸甲酯的制备
采用类似实施例1的方法，制得N-(2,2-二氯乙酰基)-3-氯-2-[(5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-基)磺酰氨基]苯甲酸甲酯，HPLC纯度97.1％。1H NMR(400MHz,D6-DMSO)δ:8.00～8.05(m,2H)，7.78(t,1H)，7.41(s,1H)，4.73(q,2H)，3.67(s,3H)，1.51(t,3H)。
实施例16 N-(2-甲氧基乙酰基)-N-[2,4-二氯-5-(4-二氟甲基-4,5-二氢-3-甲基-5-氧代-1H-1,2,4-三唑-1-基)苯基]甲磺酰胺的制备
采用类似实施例1的方法，制得N-(2-甲氧基乙酰基)-N-[2,4-二氯-5-(4-二氟甲基-4,5-二氢-3-甲基-5-氧代-1H-1,2,4-三唑-1-基)苯基]甲磺酰胺，HPLC纯度95.9％。1H NMR(400MHz,D6-DMSO)δ:8.19(s,1H)，8.10(s,1H)，7.46～7.65(m,1H)，3.96～3.98(m,1H)，3.80～3.83(m,1H)，3.62(s,3H)，3.26(s,3H)，2.42(s,3H)。
实施例17 N-苯甲酰基-N-[2,4-二氯-5-(4-二氟甲基-4,5-二氢-3-甲基-5-氧代-1H-1,2,4-三唑-1-基)苯基]甲磺酰胺的制备
采用类似实施例1的方法，制得N-苯甲酰基-N-[2,4-二氯-5-(4-二氟甲基-4,5-二氢-3-甲基-5-氧代-1H-1,2,4-三唑-1-基)苯基]甲磺酰胺，HPLC纯度99.8％。1H NMR(400MHz,D6-DMSO)δ:8.22(s,1H)，7.97(s,1H)，7.54(s,2H)，7.48(t,2H)，7.34(t,2H)，7.31(t,2H)，3.70(s,3H)，2.40(s,3H)。
实施例18 N-乙酰基-N-[2,4-二氯-5-(4-二氟甲基-4,5-二氢-3-甲基-5-氧代-1H-1,2,4-三唑-1-基)苯基]甲磺酰胺的制备
采用类似实施例1的方法，制得N-乙酰基-N-[2,4-二氯-5-(4-二氟甲基-4,5-二氢-3-甲基-5-氧代-1H-1,2,4-三唑-1-基)苯基]甲磺酰胺，HPLC纯度99.8％。1H NMR(400MHz,D6-DMSO)δ:8.20(s,1H)，8.08(s,1H)，7.46～7.64(m,1H)，3.60(s,3H)，2.42(s,3H)，2.00(s,3H)。
实施例19 N-(2-氯乙酰基)-N-[2,4-二氯-5-(4-二氟甲基-4,5-二氢-3-甲基-5-氧代-1H-1,2,4-三唑-1-基)苯基]甲磺酰胺的制备
采用类似实施例1的方法，制得N-(2-氯乙酰基)-N-[2,4-二氯-5-(4-二氟甲基-4,5-二氢-3-甲基-5-氧代-1H-1,2,4-三唑-1-基)苯基]甲磺酰胺，HPLC纯度95.8％。1H NMR(400MHz,D6-DMSO)δ:8.19(s,1H)，8.10(s,1H)，7.48～7.65(m,1H)，4.27(s,2H)，3.64(s,3H)，2.42(s,3H)。
实施例20 N-(2,2-二氯乙酰基)-N-[2,4-二氯-5-(4-二氟甲基-4,5-二氢-3-甲基-5-氧代-1H-1,2,4-三唑-1-基)苯基]甲磺酰胺的制备
采用类似实施例1的方法，制得N-(2,2-二氯乙酰基)-N-[2,4-二氯-5-(4-二氟甲基-4,5-二氢-3-甲基-5-氧代-1H-1,2,4-三唑-1-基)苯基]甲磺酰胺，HPLC纯度95.8％。1H NMR(400MHz,D6-DMSO)δ:8.17(s,1H)，7.65(s,1H)，7.46～7.66(m,1H)，6.65(s,1H)，3.70(s,3H)，2.42(s,3H)。
实施例21 N-(2-甲氧基乙酰基)-N-(2,6-二氟苯基)-5-乙氧基-8-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺的制备
采用类似实施例1的方法，制得N-(2-甲氧基乙酰基)-N-(2,6-二氟苯基)-5-乙氧基-8-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺，HPLC纯度98.6％。1H NMR(400MHz,D6-DMSO)δ：8.41(d，1H)，7.71～7.74(m，1H)，7.41(t，2H)，4.35(s，2H)，4.26(s，3H)，3.25(s，3H)。
实施例22 N-苯甲酰基-N-(2,6-二氟苯基)-5-乙氧基-8-氟-[1,2,4]三唑并[1,5-c]嘧啶-2-磺酰胺的制备
采用类似实施例1的方法，制得N-苯甲酰基-N-(2,6-二氟苯基)-5-乙氧基-8-氟-1,2,4-三唑[1,5-c]嘧啶-2-磺酰苯胺，HPLC纯度98.5％。1H NMR(400MHz,D6-DMSO)δ：8.40(d，1H)，7.56～7.59(m，1H)，7.51(t，2H)，7.42(d，1H)，7.37(t，2H)，7.28(t，2H)，4.27(s，3H)。
实施例23 N-乙酰基-N-(2,6-二氟苯基)-5-甲基-1,2,4-三唑并[1,5-a]嘧啶-2-磺酰胺的制备
采用类似实施例1的方法，制得N-乙酰基-N-(2,6-二氟苯基)-5-甲基-1,2,4-三唑并[1,5-a]嘧啶-2-磺酰胺，HPLC纯度97.9％。1H NMR(400MHz,D6-DMSO)δ：9.45(d，1H)，7.66(d，1H)，7.55(d，1H)，7.36(t，2H)，2.71(s，3H),2.38(s，3H)。
实施例24 N-(2-氯乙酰基)-N-(2,6-二氟苯基)-5-甲基-1,2,4-三唑并[1,5-a]嘧啶-2-磺酰胺的制 备
采用类似实施例1的方法，制得N-(2-氯乙酰基)-N-(2,6-二氟苯基)-5-甲基-1,2,4-三唑并[1,5-a]嘧啶-2-磺酰胺，HPLC纯度99.2％。1H NMR(400MHz,D6-DMSO)δ：9.46(d，1H)，7.70～7.73(m，1H)，7.57(d，1H)，7.38(t，2H)，4.27(s，2H)，2.69(s，3H)。
实施例25 N-(2,2-二氯乙酰基)-N-(2,6-二氟苯基)-5-甲基-1,2,4-三唑并[1,5-a]嘧啶-2-磺酰胺的制备
采用类似实施例1的方法，制得N-(2,2-二氯乙酰基)-N-(2,6-二氟苯基)-5-甲基-1,2,4-三唑并[1,5-a]嘧啶-2-磺酰胺，HPLC纯度97.2％。1H NMR(400MHz,D6-DMSO)δ:9.45(d，1H)，7.71(d，1H)，7.55(d，1H)，7.36(t，2H)，7.17(s，1H)，2.69(s，3H)。
实施例26 N-(2-甲氧基乙酰基)-N-(2,6-二氟苯基)-5-甲基-1,2,4-三唑并[1,5-a]嘧啶-2-磺酰胺的制备
采用类似实施例1的方法，制得N-(2-甲氧基乙酰基)-N-(2,6-二氟苯基)-5-甲基-1,2,4-三唑并[1,5-a]嘧啶-2-磺酰胺，HPLC纯度98.8％。1H NMR(400MHz,D6-DMSO)δ:9.45(d，1H)，7.68～7.70(m，1H)，7.55(d，1H)，7.36(t，2H)，4.50(s，2H)，3.28(s，3H)，2.71(s，3H)。
实施例27 N-乙酰基-N-(2,6-二氟苯基)-5-乙氧基-8-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺的制备
采用类似实施例1的方法，制得N-乙酰基-N-(2,6-二氟苯基)-5-乙氧基-8-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺，HPLC纯度99.3％。1H NMR(400MHz,D6-DMSO)δ：8.41(d，1H)，7.69～7.72(m，1H)，7.41(t，2H)，4.25(s，3H)，2.33(s，3H)。
实施例28 N-叔丁氧羰基-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺的制备
采用类似实施例1的方法，制得N-叔丁氧羰基-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺，HPLC纯度96.8％。1H NMR(400MHz,D6-DMSO)δ:1.43(t，3H)，1.67(s，9H)，4.78(q，2H)，6.82(s，1H)，7.22(t，1H)，7.35(d，2H)。
实施例29 N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺的制备
将实施例28制备的N-叔丁氧羰基-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺(5.06g，1.0eq)，浓盐酸1mL，乙醇(50mL)投入一装有机械搅拌的250mL反应瓶中，升温至60℃后继续搅拌反应约2h，HPLC监测原料反应完全，将反应液冷却室温， 过滤，滤饼用少量乙醇洗涤，干燥至恒重得3.97g白色固体，HPLC纯度99.9％。1H NMR(400MHz,D6-DMSO)δ:11.05(s,1H)，7.51(m,2H)，7.37(m,2H)，4.65(m,2H)，1.47(m,3H)。
实施例30 N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺的制备
将实施例1制备的N-乙酰基-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺(10.3g，1.0eq)，无水碳酸钠(2.4g，1.0eq)，无水甲醇(100mL)投入一装有机械搅拌的250mL反应瓶中，升温至55℃后继续搅拌反应约5h，HPLC监测原料反应完全，将反应液冷却室温，过滤，滤饼用冷水洗涤，过滤，干燥至恒重得8.3g白色固体，HPLC纯度99.9％。1H NMR(400MHz,D6-DMSO)δ:11.05(s,1H)，7.51(m,2H)，7.37(m,2H)，4.65(m,2H)，1.47(m,3H)。
实施例31 N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺的制备
将实施例2制备的N-(2-溴乙酰基)-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺(12.3g，1.0eq)，碳酸氢钠(2.0g，1.0eq)，无水异丙醇(100mL)投入一装有机械搅拌的250mL反应瓶中，升温至60℃后继续搅拌反应约6h，HPLC监测原料反应完全，将反应液冷却室温，过滤，滤饼用冷水洗涤，过滤，干燥至恒重得8.0g白色固体，HPLC纯度99.9％。1H NMR(400MHz,D6-DMSO)δ:11.05(s,1H)，7.51(m,2H)，7.37(m,2H)，4.65(m,2H)，1.47(m,3H)。
实施例32 N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺的制备
将实施例3制备的N-(2-氯乙酰基)-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺(11.4g，1.0eq)，碳酸钾(3.2g，1.0eq)，无水乙醇(100mL)投入一装有机械搅拌的250mL反应瓶中，升温至60℃后继续搅拌反应约6h，HPLC监测原料反应完全，将反应液冷却室温，过滤，滤饼用冷水洗涤，过滤，干燥至恒重得8.4g白色固体，HPLC纯度99.9％。1H NMR(400MHz,D6-DMSO)δ:11.05(s,1H)，7.51(m,2H)，7.37(m,2H)，4.65(m,2H)，1.47(m,3H)。
实施例33 N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺的制备
将实施例4制备的N-(2,2-二氯乙酰基)-N-(2,6-二氯苯基)-5-乙氧基-7-氟-1,2,4-三唑并[1,5-c]嘧啶-2-磺酰胺(11.6g，1.0eq)，碳酸钾(2.0g，1.0eq)，无水乙醇(100mL)投入一装有机械搅拌的250mL反应瓶中，升温至60℃后继续搅拌反应约6h，HPLC监测原料反应完全，将反应液冷却室温，过滤，滤饼用冷水洗涤，过滤，干燥至恒重得7.9g白色固体，HPLC纯度99.9％。1H NMR(400MHz,D6-DMSO)δ:11.05(s,1H)，7.51(m,2H)，7.37(m,2H)，4.65(m, 2H)，1.47(m,3H)。

Claims (9)

  1. 一种制备高纯度磺胺化合物的方法，其特征在于包括如下步骤：
    第一步，以磺胺化合物(Ⅰ)粗品为起始原料，在溶剂、碱和催化剂作用下与式(II)化合物反应合成式(III)化合物；
    第二步，将式(III)所示化合物在溶剂中与碱或酸反应，制得高纯度的磺胺化合物(I)；反应通式如下：
    Figure PCTCN2015073945-appb-100001
    其中，R为甲基或如下所示的芳基或杂芳基：
    Figure PCTCN2015073945-appb-100002
    Ar为如下所示的芳基或杂芳基：
    Figure PCTCN2015073945-appb-100003
    X为卤素或叔丁氧基羰氧基，
    Y为C1-C6烷基，C6-C12芳基或叔丁氧基。
  2. 根据权利要求1所述的方法，其特征在于：所述的X优选为Cl或叔丁氧基羰氧基，Y优选为C1-C6烷基或叔丁氧基。
  3. 根据权利要求1所述的方法，其特征在于：化合物(II)与磺胺化合物(Ⅰ)粗品的摩尔比为0.8～2:1。
  4. 根据权利要求1所述的方法，其特征在于：第一步所述的碱为有机碱；有机碱与磺胺化合物(Ⅰ)粗品的摩尔比为1～2:1，所述的催化剂为4-二甲氨基吡啶，催化剂与磺胺化合物(Ⅰ)粗品的重量百分比为0.05～10％，所述的溶剂为卤代烃、醚类或腈类，所述的反应温度为-10℃～80℃。
  5. 根据权利要求4所述的方法，其特征在于：第一步所述的有机碱优选为三乙胺、DBU或吡啶，所述的有机碱与磺胺化合物(Ⅰ)粗品的摩尔比优选为1～1.3:1，催化剂与磺胺化合物(Ⅰ)粗品的重量百分比优选为0.1～5％，所述的溶剂优选为二氯甲烷、四氢呋喃或乙腈，所述的反应温度优选为0℃～40℃。
  6. 根据权利要求1所述的方法，其特征在于：第二步所述的碱为碱金属和碱土金属的氢氧化物、碳酸盐、碳酸氢盐，碱与化合物(III)的摩尔比为0.5～1.5:1，所述的溶剂为甲醇、乙醇、异丙醇、乙腈、丙酮、DMF或DMSO，反应温度为0℃～80℃；或第二步所述的酸为无机酸或有机酸，酸与化合物(III)的摩尔比为0.5～1.5:1，溶剂为甲醇、乙醇、异丙醇、乙腈、丙酮、DMF或DMSO，反应温度为0℃～80℃。
  7. 根据权利要求6所述的方法，其特征在于：第二步所述的碱优选为碳酸钠、碳酸钾、碳酸氢钠或碳酸氢钾，碱与化合物(III)的摩尔比优选为0.75～1.25:1，溶剂优选为乙醇，反应温 度优选为10℃～60℃；或第二步所述的酸优选为盐酸、硫酸或三氟醋酸，酸与化合物(III)的摩尔比优选为0.75～1.25:1，溶剂优选为乙醇，反应温度优选为10℃～60℃。
  8. 一类磺胺化合物，其特征在于：所述的化合物结构如式(III)所示：
    Figure PCTCN2015073945-appb-100004
    其中，R为甲基或如下所示的芳基或杂芳基：
    Figure PCTCN2015073945-appb-100005
    Ar为如下所示的芳基或杂芳基：
    Figure PCTCN2015073945-appb-100006
    Y为C1-C6烷基，C6-C12芳基或叔丁氧基。
  9. 根据权利要求8所述的一类磺胺化合物，其特征在于：所述的Y优选为C1-C6烷基或叔丁氧基。
PCT/CN2015/073945 2015-03-10 2015-03-10 一种制备高纯度磺胺化合物的方法及其中间体 WO2016141548A1 (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201580075876.5A CN107406450B (zh) 2015-03-10 2015-03-10 一种制备高纯度磺胺化合物的方法及其中间体
PCT/CN2015/073945 WO2016141548A1 (zh) 2015-03-10 2015-03-10 一种制备高纯度磺胺化合物的方法及其中间体
BR112017019116-4A BR112017019116B1 (pt) 2015-03-10 2015-03-10 Método para preparar composto de sulfonamida de alta pureza e intermediário do composto de sulfonamida
US15/700,136 US9950997B2 (en) 2015-03-10 2017-09-10 Method for preparing high-purity sulfonamide compound, and intermediate of sulfonamide compound
US15/924,225 US10221128B2 (en) 2015-03-10 2018-03-18 Intermediate of preparing high-purity sulfonamide compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/073945 WO2016141548A1 (zh) 2015-03-10 2015-03-10 一种制备高纯度磺胺化合物的方法及其中间体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/700,136 Continuation US9950997B2 (en) 2015-03-10 2017-09-10 Method for preparing high-purity sulfonamide compound, and intermediate of sulfonamide compound

Publications (1)

Publication Number Publication Date
WO2016141548A1 true WO2016141548A1 (zh) 2016-09-15

Family

ID=56878737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/073945 WO2016141548A1 (zh) 2015-03-10 2015-03-10 一种制备高纯度磺胺化合物的方法及其中间体

Country Status (4)

Country Link
US (2) US9950997B2 (zh)
CN (1) CN107406450B (zh)
BR (1) BR112017019116B1 (zh)
WO (1) WO2016141548A1 (zh)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0142152A2 (en) * 1983-11-14 1985-05-22 The Dow Chemical Company Novel substituted 1,2,4-triazolo- [1,5-a] pyrimidine-2-sulfonamides and compositions and methods of controlling undesired vegetation and suppressing the nitrification of ammonium nitrogen in soil
WO1987003782A1 (en) * 1985-12-20 1987-07-02 Fmc Corporation Herbicidal aryl triazolinones
US5163995A (en) * 1988-05-25 1992-11-17 Dowelanco Herbicidal alkoxy-1,2,4-triazolo[1,5-c]pyrimidine-2-sulfonamides
WO1998013367A1 (en) * 1996-09-24 1998-04-02 Dow Agrosciences Llc N-([1,2,4] triazoloazinyl)benzenesulfonamide and pyridinesulfonamide compounds and their use as herbicides
WO1998037065A1 (en) * 1997-02-19 1998-08-27 E.I. Du Pont De Nemours And Company N-arylsulfonamide- and pyrrolidinecarboxylic acid intermediates, and their use for the preparation of herbicidal 1,3-dioxo-1h-pyrrolo[1,2-c]imidazole derivatives
WO2002036595A2 (en) * 2000-11-03 2002-05-10 Dow Agrosciences Llc N-(5,7-DIMETHOXY[1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YL) ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES
WO2005097793A1 (en) * 2004-03-26 2005-10-20 Dow Agrosciences Llc An improved process for the preparation of n-([1,2,4]triazolopyrimidin-2-yl)aryl sulfonamides
CN104447756A (zh) * 2014-11-10 2015-03-25 常州大学 一种五氟磺草胺中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954163A (en) * 1983-11-14 1990-09-04 The Dow Chemical Company Substituted 1,2,4-triazolo[1,5-a]pyrimidine-2-sulfonamides, compositions containing them, and their utility as herbicides
US4822404A (en) * 1984-01-26 1989-04-18 The Dow Chemical Company Sulfonamides derived from substituted 2-amino-1,2,4-triazolo (1,5-a) pyrimidines and compositions and methods of controlling undesired vegetation
CA1244826A (en) * 1984-01-26 1988-11-15 William A. Kleschick Sulfonamides derived from substituted 2-amino-1,2,4- triazolo(1,5-a)-pyrimidines and compositions and methods of controlling undesired vegetation
DE3539386A1 (de) * 1985-11-04 1987-05-14 Schering Ag N-(s-triazolo(1,5-a)pyrimidin-2-yl)-2-alkoxy-benzolsulfonamide, verfahren zur herstellung dieser verbindungen sowie diese enthaltende mittel mit herbizider und pflanzenwachstumsregulierender wirkung
US4910306A (en) 1987-11-09 1990-03-20 The Dow Chemical Company Preparation of substituted 1,2,4-triazolo[1,5-a]pyrimidine-2-sulfonanilides
GB8830182D0 (en) * 1988-12-23 1989-02-22 Shell Int Research Heterocyclic herbicides
ZA9710197B (en) 1996-11-13 1999-05-12 Dow Agrosciences Llc N-arylsulfilimine compounds and their use as catalysts in the preparation of n-arylarylsulfonamide compounds
WO2002032859A1 (fr) * 2000-10-18 2002-04-25 Takeda Chemical Industries, Ltd. Procede de preparation de sulfonamides optiquement actifs et intermediaires pour leur synthese
JP2013544894A (ja) * 2010-12-09 2013-12-19 ヤンセン ファーマシューティカ エヌ．ベー． Ｔｒｐｍ８モジュレータとしてのイミダゾ［１，２−ａ］ピリジンスルホンアミド

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0142152A2 (en) * 1983-11-14 1985-05-22 The Dow Chemical Company Novel substituted 1,2,4-triazolo- [1,5-a] pyrimidine-2-sulfonamides and compositions and methods of controlling undesired vegetation and suppressing the nitrification of ammonium nitrogen in soil
WO1987003782A1 (en) * 1985-12-20 1987-07-02 Fmc Corporation Herbicidal aryl triazolinones
US5163995A (en) * 1988-05-25 1992-11-17 Dowelanco Herbicidal alkoxy-1,2,4-triazolo[1,5-c]pyrimidine-2-sulfonamides
WO1998013367A1 (en) * 1996-09-24 1998-04-02 Dow Agrosciences Llc N-([1,2,4] triazoloazinyl)benzenesulfonamide and pyridinesulfonamide compounds and their use as herbicides
WO1998037065A1 (en) * 1997-02-19 1998-08-27 E.I. Du Pont De Nemours And Company N-arylsulfonamide- and pyrrolidinecarboxylic acid intermediates, and their use for the preparation of herbicidal 1,3-dioxo-1h-pyrrolo[1,2-c]imidazole derivatives
WO2002036595A2 (en) * 2000-11-03 2002-05-10 Dow Agrosciences Llc N-(5,7-DIMETHOXY[1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YL) ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES
WO2005097793A1 (en) * 2004-03-26 2005-10-20 Dow Agrosciences Llc An improved process for the preparation of n-([1,2,4]triazolopyrimidin-2-yl)aryl sulfonamides
CN104447756A (zh) * 2014-11-10 2015-03-25 常州大学 一种五氟磺草胺中间体的制备方法

Also Published As

Publication number Publication date
BR112017019116A2 (pt) 2018-04-17
US10221128B2 (en) 2019-03-05
US20180201574A1 (en) 2018-07-19
US9950997B2 (en) 2018-04-24
CN107406450A (zh) 2017-11-28
US20170369429A1 (en) 2017-12-28
BR112017019116B1 (pt) 2022-02-01
CN107406450B (zh) 2019-06-04

Similar Documents

Publication Publication Date Title
ES2563211T3 (es) Procedimiento para la preparación de compuestos de aminocrotonilo
ES2513441T3 (es) Procedimiento para la preparación de compuestos farmacéuticamente activos
CN106243046B (zh) 一种甲基二磺隆的制备方法
AU2005230862A1 (en) An improved process for the preparation of N-((1,2,4)triazolopyrimidin-2-yl)aryl sulfonamides
JP2018518489A (ja) アプレミラスト及びその中間体の調製方法
JP7025411B2 (ja) インドールカルボキサミド化合物の製造方法
TWI488856B (zh) 用於製備二硫雜己環并（ｄｉｔｈｉｉｎｅ）－四羧醯亞胺類之方法
MXPA04008109A (es) Metodo para preparar cloruro de bencisoxasol metano sulfonilo y su amidacion para formar zonisamida.
CN110204464B (zh) 一种芳基叔磺酰胺类化合物的合成方法
WO2016141548A1 (zh) 一种制备高纯度磺胺化合物的方法及其中间体
US7109353B2 (en) Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCl
US6531605B1 (en) Process for the manufacture of arylsulfonyl chloride
CN112707835B (zh) 一种间二酰胺类化合物的溴化方法
JP4030683B2 (ja) ベンズアミド誘導体の合成法
MXPA05002745A (es) Sintesis de indolizinas.
JP4551762B2 (ja) ３，４−ジクロロ−ｎ−（２−シアノフェニル）−５−イソチアゾールカルボキサミドの製造方法
KR100900177B1 (ko) 트리테르펜 유도체의 제조 방법
JP2004224714A (ja) イソオキサゾリジン−３−チオン誘導体の製造法
WO2012027951A1 (zh) 一种合成培南类药物的中间体及其制备方法和应用
JP4061333B2 (ja) ２−（ピラゾール−１−イル）ピリジン誘導体
CN110903245B (zh) 一种合成1-烷基-2-三氟甲基-5-氨基-1h-咪唑的关键中间体及其制备方法
EP1371638A1 (en) Pyridazinone derivatives as intermediates of herbicides
MX2007007923A (es) Procedimiento para preparar clorhidrato de 5,6-dihidro-4-(s)- (etilamino)-6-(s)metil-4h-tieno[2,3b]tiopiran-2-sulfonamida-7,7- dioxido.
JP3646223B2 (ja) 求電子反応による芳香族化合物の製造方法及び芳香族化合物
JP3013414B2 (ja) ピラゾール―５―カルボン酸エステル類の製造法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15884231

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017019116

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017019116

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170906

122 Ep: pct application non-entry in european phase

Ref document number: 15884231

Country of ref document: EP

Kind code of ref document: A1